Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOLLY L HAKE HARRIS

Allopathic & Osteopathic Physicians Dermatology

NPI
1538159207
CMS profile
890706
Location
SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$60.71

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $60.71 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $24.01 1
GENZYME CORPORATION $19.62 1
Lilly USA, LLC $17.08 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOLLY L HAKE HARRIS

NPI 1538159207 · CMS profile ID 890706

Allopathic & Osteopathic Physicians / Dermatology

SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $60.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $24.0107/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201991368 CMS
GENZYME CORPORATION $19.6204/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233695767 CMS
Lilly USA, LLC $17.0804/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186600368 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,931.99 7
PY2021 $29.68 2
PY2022 $77.19 4
PY2023 $448.39 16
PY2024 $189.69 8
PY2025 $60.71 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,042.82 1
PY2025 Principal investigator $214,389.75 98
PY2024 Recipient $6,347.66 1
PY2024 Principal investigator $293,318.73 162
PY2023 Principal investigator $348,782.35 197
PY2022 Recipient $100.00 2
PY2022 Principal investigator $164,469.18 81
PY2021 Principal investigator $449,676.56 73
PY2020 Recipient $15,456.30 2
PY2020 Principal investigator $642,662.67 80
PY2019 Recipient $418,491.34 8
PY2019 Principal investigator $1,194,399.32 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $4,330.12 12/31/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792488917
Principal investigator 1 ABBVIE INC. $84.00 12/31/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792489075
Principal investigator 1 PFIZER INC. $1,722.50 12/08/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832561059
Principal investigator 1 ABBVIE INC. $1,453.70 12/02/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792484673
Principal investigator 1 ABBVIE INC. $1,325.20 12/02/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792484951
Principal investigator 1 ABBVIE INC. $2,197.80 11/26/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792484337
Principal investigator 1 PFIZER INC. $1,722.50 11/23/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832604793
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,588.14 11/16/2021 Non-covered Recipient Entity
South Bend Clinic
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 819900897
Principal investigator 1 ABBVIE INC. $1,437.00 11/10/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792482351
Principal investigator 1 PFIZER INC. $2,384.40 11/05/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832838459
Principal investigator 1 ABBVIE INC. $778.00 11/04/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792481061
Principal investigator 1 ABBVIE INC. $5,852.50 11/04/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792481063
Principal investigator 1 PFIZER INC. $5,260.00 10/09/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832854081
Principal investigator 1 Eli Lilly and Company $331.10 10/08/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819467323
Principal investigator 1 ABBVIE INC. $2,005.40 10/07/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792478433
Principal investigator 1 ABBVIE INC. $3,658.50 10/06/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792477369
Principal investigator 1 ABBVIE INC. $1,453.70 10/06/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792477371
Principal investigator 1 Eli Lilly and Company $683.10 09/27/2021 Non-covered Recipient Entity
COLORADO NEUROLOGICAL INSTITUTE
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 819456167
Principal investigator 1 PFIZER INC. $1,744.50 09/22/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832601479
Principal investigator 1 PFIZER INC. $1,722.50 09/04/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832604335
Principal investigator 1 ABBVIE INC. $1,848.90 08/30/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792473031
Principal investigator 1 ABBVIE INC. $2,907.40 08/30/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792473033
Principal investigator 1 ABBVIE INC. $7,188.90 08/26/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792472803
Principal investigator 1 PFIZER INC. $2,676.70 08/24/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832604325
Principal investigator 1 PFIZER INC. $11,192.50 08/24/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832914569
Principal investigator 1 Eli Lilly and Company $2,672.00 08/23/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 819464709
Principal investigator 1 ABBVIE INC. $1,634.60 08/19/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792472441
Principal investigator 1 PFIZER INC. $1,744.50 08/06/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832602255
Principal investigator 1 ABBVIE INC. $1,886.60 07/29/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792468993
Principal investigator 1 PFIZER INC. $2,044.25 07/21/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832601489
Principal investigator 1 PFIZER INC. $2,925.00 07/09/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832813906
Principal investigator 1 ABBVIE INC. $1,325.20 06/30/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792464871
Principal investigator 1 PFIZER INC. $3,445.00 06/23/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832601449
Principal investigator 1 PFIZER INC. $3,644.55 06/05/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832604803
Principal investigator 1 ABBVIE INC. $1,848.90 05/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792459955
Principal investigator 1 ABBVIE INC. $7,395.60 05/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792459957
Principal investigator 1 PFIZER INC. $3,127.15 05/25/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832602265
Principal investigator 1 PFIZER INC. $2,675.40 05/22/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832702139
Principal investigator 1 Eli Lilly and Company $51.00 05/10/2021 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819448261
Principal investigator 1 Eli Lilly and Company $30.60 05/10/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JR UNIV
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819453703
Principal investigator 1 Eli Lilly and Company $96.00 05/10/2021 Non-covered Recipient Entity
CHILDRENS RESEARCH INSTITUTE
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819454547
Principal investigator 1 Eli Lilly and Company $144.00 05/10/2021 Non-covered Recipient Entity
MOUNT SINAI SCHOOL OF MEDICINE
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819463907
Principal investigator 1 ABBVIE INC. $3,340.30 04/29/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792447845
Principal investigator 1 ABBVIE INC. $1,848.90 04/29/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792447849
Principal investigator 1 ABBVIE INC. $1,886.60 04/29/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792447855
Principal investigator 1 ABBVIE INC. $3,735.50 04/29/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792447861
Principal investigator 1 PFIZER INC. $1,722.50 04/22/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832604783
Principal investigator 1 PFIZER INC. $2,022.80 04/09/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832764905
Principal investigator 1 Eli Lilly and Company $0.99 04/08/2021 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819449065
Principal investigator 1 Eli Lilly and Company $7.65 04/08/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER - NEUROSCIENCE RESEARCH INSTITUTE
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819450237
Principal investigator 1 Eli Lilly and Company $117.30 04/08/2021 Non-covered Recipient Entity
CINCINNATI RHEUMATIC DISEASE STUDY GROUP INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819453851
Principal investigator 1 Eli Lilly and Company $37.50 04/08/2021 Non-covered Recipient Entity
DALLAS DIABETES AND ENDO RESEARCH CENTER PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819455623
Principal investigator 1 Eli Lilly and Company $153.80 04/08/2021 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819460755
Principal investigator 1 Eli Lilly and Company $96.00 04/08/2021 Non-covered Recipient Entity
PAUL NORWOOD MD DBA VALLEY RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819462073
Principal investigator 1 Eli Lilly and Company $1.60 04/08/2021 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819469415
Principal investigator 1 ABBVIE INC. $3,340.30 04/01/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792440597
Principal investigator 1 ABBVIE INC. $1,970.30 03/30/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792437453
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $39,919.05 03/30/2021 Non-covered Recipient Entity
South Bend Clinic Llp
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819900903
Principal investigator 1 PFIZER INC. $4,727.45 03/24/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832601459
Principal investigator 1 PFIZER INC. $4,698.20 03/24/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832914579
Principal investigator 1 Eli Lilly and Company $9,306.00 03/16/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819464967
Principal investigator 1 PFIZER INC. $1,744.50 03/06/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832601499
Principal investigator 1 Eli Lilly and Company $174,295.19 03/02/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 819464965
Principal investigator 1 Eli Lilly and Company $19,098.00 03/02/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819465621
Principal investigator 1 PFIZER INC. $1,600.30 02/05/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832604317
Principal investigator 1 PFIZER INC. $4,045.60 02/05/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832905911
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,306.60 02/02/2021 Non-covered Recipient Entity
South Bend Clinic Llp
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 819900909
Principal investigator 1 ABBVIE INC. $1,325.20 01/28/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792414921
Principal investigator 1 Eli Lilly and Company $1,951.32 01/26/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 819467549
Principal investigator 1 Eli Lilly and Company $424.30 01/11/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819464763
Principal investigator 1 PFIZER INC. $6,068.40 01/09/2021 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832729039
Principal investigator 1 Eli Lilly and Company $32,550.00 01/05/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 819468891
Principal investigator 1 Eli Lilly and Company $8,095.00 01/05/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819468897

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $109,356.47 1
PY2024 Amount invested $2,443.72 1
PY2024 Value of interest $109,356.47 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $106,912.75 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $154,320.92 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $88,340.48 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $80,642.76 1
PY2019 Amount invested $80,595.00 1
PY2019 Value of interest $806,985.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Digital Diagnostics Inc. $0.00 $109,356.47 Shares Owned by Immediate Family (Ben Clark) Immediate family member No dispute reported 06/30/2026 1254605365
PY2024 Digital Diagnostics Inc. $2,443.72 $109,356.47 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1153967797
PY2023 Digital Diagnostics Inc. $0.00 $106,912.75 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1060331987
PY2022 Digital Diagnostics Inc. $0.00 $154,320.92 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 961154523
PY2021 Digital Diagnostics Inc. $0.00 $88,340.48 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 855625849
PY2020 Digital Diagnostics Inc. $0.00 $80,642.76 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 737170185
PY2019 IDx Technologies Inc. $80,595.00 $806,985.00 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 676471935